Navigation Links
Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
Date:8/13/2009

usiness is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this Quarterly Report on Form 10-Q to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission ("SEC"). For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended June 30, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Calif. , July 25, 2014 Amgen ... of Directors today declared a $0.61 per share dividend ... be paid on Sept. 5, 2014, to all stockholders ... Aug. 14, 2014.  About Amgen Amgen ... patients suffering from serious illnesses by discovering, developing, manufacturing ...
(Date:7/25/2014)... CAMBRIDGE, MA -- Trillions of bacteria live in each ... bacteria help digest food and stave off harmful infections, ... understood. , To help shed light on the role ... MIT associate professor Eric Alm recently tracked fluctuations in ... full year. The findings, described in the July 25 ...
(Date:7/25/2014)... University of Leicester has furthered our understanding of ... create new materials using nanosized ,building blocks,. , ... prestigious academic journal Physical Review Letters , ... rich detail the structure and internal atomic motion ... and a single helium atom. , The technique ...
(Date:7/25/2014)... 2014 Research and Markets  has ... Market 2014-2018" report to their offering. ... Metabolomics or Metabonomics is the scientific study of ... new experimental technique that is being widely used ... are small molecules that are present in blood, ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2
... Calif., Oct. 11 CompareNetworks,Media Group, the leading ... industries, today announced the launch of Acuity Medical,Education, ... CompareNetworks. With the arrival of two key new ... Liza Frenzik as Special,Projects Director, the CompareNetworks team ...
... Phase 2 monotherapy trial to be initiated by end ... Biogen Idec,Inc. (Nasdaq: BIIB ) and PDL ... Phase 2 data demonstrated a significant reduction in new ... therapy in patients with active relapsing multiple,sclerosis (MS). These ...
... HAYWARD, Calif., Oct. 11 Guava Technologies today,launched ... around its,main audiences: Life Scientists, Flow Cytometrists, and ... tool for cell analysis, Guava,Technologies is dedicated to ... as possible for all life scientists and clinicians ...
Cached Biology Technology:CompareNetworks Media Group Delivers CME/CE Through Acuity Medical Education 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 2Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 3Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 4Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 5Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy 6New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians 2
(Date:7/25/2014)... the Stowers Institute for Medical Research have ... and found pheromones crucial to triggering the mating process ... helps a male mouse detect pheromones that indicate when ... lets him know if the female mouse is ovulating ... critical to trigger mating. Stowers, researchers believe mice developed ...
(Date:7/25/2014)... researchers have detected an unknown interaction between microorganisms and ... into a droplet of salt water and is left ... create biomineralogical biosaline 3D morphologically complex formations, where they ... revived. The discovery was made by chance with a ... Astrobiology journal and may help to find ...
(Date:7/24/2014)... YORK, NY (July 24, 2014) Scientists at ... Institute are one step closer to creating a ... a patient,s own cells. , For the ... (iPS) cells lines from skin samples of patients ... developed an accelerated protocol to induce these stem ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3Bacteria manipulate salt to build shelters to hibernate 2NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2
... Age-related hearing loss (ARHL), one of the four most prevalent ... levels of folic acid, according to new research published in ... Neck Surgery . Hearing loss is a major ... between the ages of 60 and 74 dealing with the ...
... Geo-microbiologists from Arizona State University have solved a ... cyanobacteria, bore their way into limestone, sand grains, ... of carbonate. According to the lead ... the mystery of what is "at the heart ...
... Davis Health System have found that compared with healthy ... in patients in the Sacramento area with metabolic syndrome, ... one in three U.S. adults and predisposes them to ... is the first to examine vitamin-D status in patients ...
Cached Biology News:Mystery dissolves with calcium pump discovery 2Mystery dissolves with calcium pump discovery 3Study finds low vitamin-d levels in northern California residents with metabolic syndrome 2Study finds low vitamin-d levels in northern California residents with metabolic syndrome 3Study finds low vitamin-d levels in northern California residents with metabolic syndrome 4
... modern flow cytometer, a scientist can resolve ... with fluorescent probes. However, the emission spectra ... labeling are broader than the light collection ... Thus, the fluorescence signal of a dye ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... ActiveSight, the leading provider of ... design, offers fragment-based screening services to ... screening involves the binding of drug-like ... crystallized protein drug targets, allowing scientists ...
...
Biology Products: